NASDAQ Healthcare Drug Manufacturers - Specialty & Generic SIGA

SIGA Technologies, Inc.

$ 4.32 0.23 %

SIGA Technologies, Inc. is a pharmaceutical company with commercialized products, specializing in the health security and infectious disease sectors across the United States. A core offering is TPOXX, an oral antiviral drug formulated to combat human smallpox, a condition caused by the variola virus. Furthermore, the company has forged a strategic collaboration with Cipla Therapeutics. This partnership aims to ensure ongoing innovation and accessibility of antibacterial treatments, particularly those designed to counter biothreats. Founded in 1995, SIGA Technologies' corporate headquarters are located in New York, New York.

CEO: Diem Nguyen - https://www.siga.com

Summary 30-Y Financials Dividend Analyst Key metrics Ownership / Senat
Price objectif

-

Recommandation

Buy

DCF

$ 10.31

Loading data...

SIGA vs S&P500

Loading data...

No data available.

Quick ratio

2.38

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

15.43

is considered reasonable, suggesting that the company has a valuation in line with its current profits.

EPS

0.28

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

10.62 %

reflects reasonable profitability, showing good use of equity.

ROIC

10.03 %

generates a return higher than the cost of its capital, thereby creating value for its investors.

WACC

8.23

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.00

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

0.38

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

213.57 %

indicates that the company is retaining a large portion of its profits to reinvest in growth

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
4 indicates moderate financial health
Altman score
3.80 indicates good financial health and low risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
2.23 indicates that the company has sufficient cash to cover its short-term debts
Debt Ratio
0.00 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.